Abera Bioscience AB (NGM:ABERA)
Sweden · Delayed Price · Currency is SEK 8.10
0.00 (0.00%)
At close: Sep 3, 2026
Abera Bioscience AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 17.71 | 23.49 | 6.09 | 3.32 | 15.43 | 11.95 |
Cash & Short-Term Investments | 17.71 | 23.49 | 6.09 | 3.32 | 15.43 | 11.95 |
Cash Growth | 122.81% | 285.70% | 83.49% | -78.50% | 29.13% | 1224.40% |
Other Receivables | 1.2 | 0.99 | 0.65 | 0.77 | 0.77 | 0.3 |
Receivables | 1.2 | 0.99 | 0.65 | 0.77 | 0.77 | 0.3 |
Prepaid Expenses | 0.5 | 0.9 | 3.91 | 3.38 | 1.49 | 0.19 |
Other Current Assets | - | - | - | - | -0 | - |
Total Current Assets | 19.41 | 25.37 | 10.65 | 7.46 | 17.69 | 12.44 |
Property, Plant & Equipment | 1.18 | 1.3 | 1.07 | - | - | - |
Long-Term Deferred Charges | 1.89 | 1.89 | 1.89 | 1.89 | 1.89 | 1.89 |
Other Long-Term Assets | -0 | - | -0 | - | - | 17.05 |
Total Assets | 22.48 | 28.57 | 13.6 | 9.35 | 19.57 | 31.37 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.31 | 1.53 | 1.23 | 2.2 | 1.67 | 0.99 |
Accrued Expenses | 0.93 | 0.84 | 0.95 | 1.23 | 0.97 | 1.17 |
Other Current Liabilities | 2.3 | 6.91 | 2.77 | 0.27 | 0.16 | 0.07 |
Total Current Liabilities | 4.55 | 9.28 | 4.95 | 3.69 | 2.8 | 2.22 |
Other Long-Term Liabilities | - | - | - | - | -0 | -0 |
Total Liabilities | 4.55 | 9.28 | 4.95 | 3.69 | 2.8 | 2.22 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1.64 | 1.48 | 1.23 | 1.16 | 1.03 | 0.84 |
Additional Paid-In Capital | 99.55 | 89.72 | 68.89 | 64.86 | 59.39 | 52.49 |
Retained Earnings | -83.27 | -71.91 | -61.46 | -60.36 | -44.11 | -24.73 |
Comprehensive Income & Other | - | - | - | 0 | 0.47 | 0.56 |
Shareholders' Equity | 17.93 | 19.29 | 8.66 | 5.66 | 16.78 | 29.15 |
Total Liabilities & Equity | 22.48 | 28.57 | 13.6 | 9.35 | 19.57 | 31.37 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 17.71 | 23.49 | 6.09 | 3.32 | 15.43 | 11.95 |
Net Cash Growth | 122.81% | 285.70% | 83.49% | -78.50% | 29.13% | 1224.40% |
Net Cash Per Share | - | 1.42 | 0.39 | 0.25 | 1.32 | 1.17 |
Filing Date Shares Outstanding | - | 20.5 | 15.35 | 14.46 | 12.91 | 11.57 |
Total Common Shares Outstanding | - | 18.63 | 15.35 | 14.46 | 12.91 | 11.57 |
Working Capital | 14.86 | 16.09 | 5.7 | 3.77 | 14.89 | 10.21 |
Book Value Per Share | - | 1.04 | 0.56 | 0.39 | 1.30 | 2.52 |
Tangible Book Value | 17.93 | 19.29 | 8.66 | 5.66 | 16.78 | 29.15 |
Tangible Book Value Per Share | - | 1.04 | 0.56 | 0.39 | 1.30 | 2.52 |